에 대한 최신 뉴스 N2OFF (NASDAQ:NITO) 주식

N2OFF

N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.

N2OFF Inc

NITORI HOLDINGS CO LTD by Nitori Holdings Co., Ltd.

Nitori Holdings Co Ltd

NITORI HOLDINGS CO U/ADR by Nitori Holdings Co., Ltd.

Needham analyst Chris Pierce maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Buy and lowers the price target from $17 to $16.

News

Price Target

Analyst Ratings

RIVN

Needham Maintains Buy on Rivian Automotive, Lowers Price Target to $16

WIIM

OSCR

Oscar Health shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance above estimates.

-&nbsp;End-of-Phase 2 meeting with FDA requested for Alzheimer's disease&nbsp;-
-&nbsp;Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC&nbsp;-
-&nbsp;Two posters at ARVO describe zervimesine's role supporting retinal cell health -
PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=S_myvafGmczBdiezo6fQYx2lz6A7kPAsgZFw5mjGC9AvcEGUj7eGPOmQ8mmRan99PAyhwo0YHJOeO5iDzvBf2tCcz92wMCgCl5titXRtWrQ=">Cognition Therapeutics, Inc.</a> (the "Company" or "Cognition") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
"During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimer's disease and dementia with Lewy bodies (DLB) programs," stated <a href="https://www.globenewswire.com/Tracker?data=hqiclI-dNxq4vyDmCB6SX6KOI1joTDXvuKybYfUFJyFI98ZGhoFV95DoHhhCOyGlPaXCveLlCyrzRST2CfhxsJN2XaeT5IPv6wo6QtR9RbX4a4UE4mA3OUPyt4pLo_NuB5cfXNsVlVl96gEV39GpF1IWWJO_UxarN9uUBnBMdyk=">Lisa Ricciardi, Cognition's president and CEO</a>. "A request was made with the U.S. Food and Drug Administration to schedule an end-of-Phase 2 (EOP2) meeting to review the results from the SHINE study in Alzheimer's disease and discuss plans for a registrational study. In order to request separate EOP2 meetings for each indication, both need to have a unique FDA program number. For that reason, we recently initiated the process of securing a commercial investigational new drug (IND) application for zervimesine (CT1812) in DLB. Once that process is complete, we will request an EOP2 for DLB."
Business and Corporate Highlights
<ul>
<li>Requested an EOP2 meeting with FDA to review the results from the SHINE study in Alzheimer's disease.</li>
<li>Phase 2 ‘SHIMMER' study results&nbsp;in DLB were accepted for a podium presentation at the Alzheimer's Association International Congress (AAIC), to be held July 27-31, 2025 in Toronto, Canada.</li>
<li>Presenting two posters at the Association for Research in Vision and Ophthalmology (ARVO) meeting describing zervimesine's role in regulating lipid metabolism and its ability to protect retinal cells from oxidized lipids, a component of drusen.</li>
<li>In January 2025 results from the Company's Phase 2 ‘SHIMMER' study&nbsp;were presented at the <a href="https://ir.cogrx.com/events/international-lewy-body-dementia-conference-ilbdc-2025/">International Lewy Body Dementia Conference (ILBDC)</a> by James E. Galvin, MD, MPH. (Director, Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine; study director and principal investigator on the SHIMMER study grant from the National Institute of Aging).</li>
</ul>

CGTX

Cognition Therapeutics Requests EOP2 Meeting With FDA To Review Results From SHINE Study In Alzheimer's Disease

Atco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACO#TSX">ACO</a>) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $1.37 by 4.38 percent. This is a 8.33 percent increase over earnings of $1.32 per share from the same period last year. The company reported quarterly sales of $1.41 billion which beat the analyst consensus estimate of $1.38 billion by 2.25 percent. This is a 6.57 percent increase over sales of $1.32 billion the same period last year.

Earnings

Earnings Beats

TSX:ACO

TSX:ACO.X

Atco Q1 Adj. EPS $1.43 Beats $1.37 Estimate, Sales $1.41B Beat $1.38B Estimate

Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.26 by 19.23 percent.

SUNS

Sunrise Realty Trust Q1 Adj. EPS $0.31 Beats $0.26 Estimate

InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26.32 percent. This is a 22.22 percent increase over losses of $(0.18) per share from the same period last year.

IFRX

InflaRx Q1 EPS $(0.14) Beats $(0.19) Estimate

Management

JLL Appoints Kelly Howe As CFO, Effective Jul. 1

MasterCraft Boat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) narrows FY2025 Adj EPS guidance from $0.64-$0.86 to $0.71 vs $0.71 analyst estimate. Narrows FY2025 sales outlook from $275.00 million-$295.00 million to $275.00 million vs $284.03 million estimate.

Guidance

MCFT

MasterCraft Boat Hldgs Narrows FY2025 Adj EPS Guidance from $0.64-$0.86 to $0.71 vs $0.71 Est; Narrows FY2025 Sales Guidance from $275.00M-$295.00M to $275.00M vs $284.03M Est

ARAY

Accuray Announced That New Data Presented At The European Society For Radiotherapy And Oncology Meeting Reinforces The Benefits Of The Company's CyberKnife System In The Treatment Of Prostate Cancer At Multiple Stages Of The Cancer Journey

Needham analyst Scott Berg maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Buy and lowers the price target from $56 to $45.

KVYO

Needham Maintains Buy on Klaviyo, Lowers Price Target to $45

EHTH

eHealth Affirms FY2025 Sales Guidance of $510.00M-$550.00M vs $529.17M Est

Spartan RV Owners Now Have Access to Expanded Service Support at 148 Rush Truck Centers Locations Across the U.S. and Canada
NOVI, Mich., May 7, 2025 /PRNewswire/ --&nbsp;Spartan&#xAE; RV Chassis, a go-to-market brand of The Shyft Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>), the North American leader in specialty vehicle manufacturing, assembly, and upfit for the commercial, retail, and service markets, today announced a strategic partnership with Rush Truck Centers, North America's largest commercial vehicle dealership network. The collaboration further strengthens Spartan RV Chassis' nationwide support infrastructure, expanding access to expert service and repair capabilities for motorhome owners across the U.S. and Canada.

SHYF

Shyft Group's Spartan RV Chassis Forms Strategic Partnership With Rush Truck Centers To Strengthen North American Service Network

MasterCraft Boat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.17 by 76.47 percent. This is a 18.92 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $75.96 million which beat the analyst consensus estimate of $74.89 million by 1.43 percent. This is a 20.63 percent decrease over sales of $95.71 million the same period last year.

MasterCraft Boat Hldgs Q3 Adj. EPS $0.30 Beats $0.17 Estimate, Sales $75.96M Beat $74.89M Estimate

eHealth Q1 Adj. EPS $(0.20) Beats $(0.42) Estimate, Sales $113.12M Beat $99.63M Estimate

Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) affirms FY2025 sales outlook from $580.00 million-$600.00 million to $580.00 million-$600.00 million vs $592.19 million estimate.

HLLY

Holley Affirms FY2025 Sales Guidance of $580.00M-$600.00M vs $592.19M Est

Elon Musk's SpaceX has received approval from the U.S. Government's Federal Aviation Administration (FAA) to scale up launches of the company's Starship rockets — a key component in the billionaire's plans to travel to Mars.
What Happened: The regulatory approval, which followed a year-long review, means that SpaceX can now increase the number of launches in Texas from 5 to 25, as well as use the water bodies for its booster landings, Reuters reported on Tuesday.
The agency reiterated that increasing Starship launches, as well as booster landings or any potential explosions, would not pose a significant threat to the water bodies like the Gulf of Mexico or the surrounding environment.
However, the report suggests that the FAA has outlined some conditions for SpaceX, including beach cleanups, donations to environmental organizations, water testing around the launch sites and more.
Why It Matters: The news comes in as NASA faces over <a href="https://www.benzinga.com/markets/25/05/45189017/nasa-prepares-for-6-billion-budget-cut-amid-shift-towards-elon-musks-mars-focused-initiatives">$6 billion in budget cuts </a>from the Trump administration in what could be described as the space agency pivoting to Mars-focused initiatives — something Musk is aspirational about.
This is also in line with Trump's pick for NASA's Chief, Jared Isaacman, who <a href="https://www.benzinga.com/general/space/25/04/44730104/trumps-nasa-chief-pick-isaacman-tells-senate-we-will-prioritize-sending-american-astronauts-to-mars">doubled down on Mars</a>. "We will prioritize sending American astronauts to Mars," Isaacman said 
Musk reiterated the company's plans to set up a <a href="https://www.benzinga.com/tech/25/05/45213809/teslas-elon-musk-says-manually-driven-cars-will-be-unusual-in-the-future-shares-updates-on-spacex-neuralink">city on Mars</a> in a recent interview. Interestingly, SpaceX's Starbase HQ was recently successfully incorporated as a city in Texas's Cameron County.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44373082/former-nasa-astronaut-predicts-mars-travel-still-15-years-away-not-5-years-as-elon-musk-alludes-to">Former NASA Astronaut Predicts Mars Travel Still 15 Years Away: &#8216;Not 5 Years As Elon Musk Alludes To&#8217;</a></li>
</ul>
Image Via Shutterstock

SPACE

Tech

General

Elon Musk's Mars Ambitions Take Flight As SpaceX Gets FAA Approval For Texas Starship Launches

Rosenblatt analyst Chris Brendler maintains Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Buy and maintains $5.5 price target.

CIFR

Rosenblatt Maintains Buy on Cipher Mining, Maintains $5.5 Price Target

Unity Software shares are trading higher following better-than-expected Q1 financial results.

Needham analyst Laura Martin maintains CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) with a Buy and raises the price target from $2.95 to $4.8.

CURI

Needham Maintains Buy on CuriosityStream, Raises Price Target to $4.8

PAYO

Payoneer, Citing Current Macroeconomic Uncertainty, Has Suspended Its Previously Issued Full-Year 2025 Guidance

Press Releases

N2OFF: Save Foods Ltd. (100%) Wins Patent Opposition Filed by ECOLAB in Europe

N2OFF and Solterra Join Forces to Exclusively Co-Develop the Solar PV Market in Albania

N2OFF and Solterra Unite to Pioneer Solar PV Development in Albania

N2OFF and Solterra Announce the Closing of a Definitive Agreement to Develop 196 MWp Battery Storage Projects in Italy

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

Contracts

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

N2OFF Establishes a US Subsidiary for Its Solar PV Operations

N2OFF Secures Definitive Agreement to Commercialize 196 MWp Battery Storage Projects

N2OFF Signs Non-Binding LOI for Potential 380MW Battery Energy Storage Projects

N2OFF Announces Potential to Maximize Investment Opportunity Following New Regulation in Germany

NITO

SPRC

American Vanguard Corporation Common Stock ($0.10 Par Value)

American Vanguard

Bioceres Crop Solutions Corp. - Ordinary Shares

Bioceres Crop Solutions

CF Industries Holdings, Inc. Common Stock

CF Industries Holdings

Corteva

Enlightify

Brazil Potash

Intrepid Potash

Mosaic

Scotts Miracle-Gro Company (The) Common Stock

Scotts Miracle Gro

CVR Partners, LP Common Units representing Limited Partner Interests

Comments

N2OFF

뉴스

에 대한 최신 뉴스 N2OFF (NASDAQ:NITO) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌